Overview

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.
Phase:
Phase 2
Details
Lead Sponsor:
PharmaKing
Treatments:
Metadoxine
Pyridoxine